Define electrolytes, list their normal serum ranges, explain their physiological regulation, identify causes of abnormal values and when urgent review is required, and describe how to correlate biochemistry results with physical examination findings.

Electrolytes: Definition, Normal Values, Physiology, and Clinical Management

Definition of Electrolytes

Electrolytes are charged ions dissolved in body fluids that maintain osmotic balance, regulate transmembrane potentials, and enable critical physiological functions. The major electrolytes include sodium (Na+), potassium (K+), chloride (Cl-), calcium (Ca2+), magnesium (Mg2+), and phosphate (PO4³-) 1. Approximately 98% of total body potassium resides intracellularly, while only 2% exists in the extracellular space, making serum measurements a small window into total body stores 2.

Normal Serum Values

Standard Reference Ranges:

• Sodium: 135-145 mmol/L (or 130-147 mmol/L in some populations) 3, 4
• Potassium: 3.5-5.3 mmol/L (or 3.1-5.0 mmol/L) 3, 4
• Chloride: 95-105 mmol/L (or 96-114 mmol/L) 3, 4
• Calcium: 4.4-5.2 mmol/L 3
• Magnesium: 1.6-2.4 mmol/L; hypomagnesemia defined as <0.70 mmol/L 3, 5
• Phosphate: 0.81-1.59 mmol/L; hypophosphatemia defined as <0.81 mmol/L 6, 4

Important caveat: Reference ranges vary by analyzer type and methodology, particularly with ion-selective electrodes versus older flame photometry methods 7. Serum sodium and chloride interpretation requires knowledge of the sample's water, lipid, and protein concentrations 8.

Physiological Regulation

Sodium and Water Balance

Sodium concentration reflects the ratio of sodium to water in the extracellular compartment rather than total body sodium content 1. Pathological sodium levels must be interpreted in the context of total body volume status 1. Arginine vasopressin (AVP) regulates water retention; nonosmotic stimuli including pain, nausea, stress, postoperative states, hypovolemia, and conditions like pneumonia or meningitis can trigger syndrome of inappropriate antidiuresis (SIAD), leading to water retention and hyponatremia 3.

Potassium Homeostasis

Potassium balance is primarily maintained by the kidneys, with gastrointestinal and other systems playing lesser roles 9. Hyperkalemia develops through three mechanisms: increased intake, reduced excretion, and intracellular-to-extracellular shifts 2. Potassium affects transmembrane potentials critical for cardiac and neuromuscular function 1.

Phosphate Regulation

Phosphate balance involves complex interactions between intestinal absorption, redistribution, and renal excretion 6. In hospitalized patients, these regulatory mechanisms are frequently disrupted, increasing hypophosphatemia risk through inadequate intake, redistribution (especially with refeeding), and losses from kidney replacement therapy 6.

Calcium and Magnesium

These divalent cations are regulated by active membrane transporters and hormones including parathyroid hormone (PTH) 1. Their extracellular concentrations influence electrophysiologically relevant transmembrane potentials 1.

Causes of Abnormal Values and Urgent Review Criteria

Hyperkalemia (K+ >5.0 mmol/L)

Classification by severity:

• Mild: >5.0 to <5.5 mmol/L 2
• Moderate: 5.5-6.0 mmol/L 2
• Severe: >6.0 mmol/L 2

Urgent review required: Potassium >6.0 mmol/L requires immediate attention, though life-threatening arrhythmias can occur at variable thresholds 2. Patients with chronic kidney disease, diabetes, or heart failure may tolerate levels up to 6.0 mmol/L without arrhythmias 2.

Common causes:

• Chronic kidney disease (prevalence up to 73% in advanced CKD) 2
• Heart failure (up to 40% prevalence) 2
• Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy 2, 10
• Diabetes mellitus 10

Management approach: Hyperkalemia with RAASi therapy should prompt measures to lower potassium while continuing cardioprotective RAASi therapy rather than discontinuation 2. Potassium-binding agents (patiromer, sodium zirconium cyclosilicate) facilitate RAASi optimization 9. Dietary restriction and concurrent diuretics or SGLT2 inhibitors help manage hyperkalemia in diabetic patients 10.

Hypokalemia

Prevalence: 12-20% in hospitalized patients, increasing to 25% in patients with kidney failure on prolonged kidney replacement therapy 5.

Urgent review: Severe hypokalemia (<2.5 mmol/L) requires immediate correction due to cardiac arrhythmia risk 5.

Hyponatremia (Na+ <135 mmol/L)

Prevalence: 15-30% of hospitalized patients 3.

Urgent review required: Acute symptomatic hyponatremia constitutes a medical emergency; hyponatremic encephalopathy can be fatal or cause irreversible brain injury 3.

Management by volume status:

• Volume deficit: Administer sodium chloride solution 11
• Volume overload: Strict water restriction; consider pharmacotherapy targeting antidiuretic hormone effects 11

Critical consideration: Hypotonic maintenance fluids (historically based on 1950s calculations) are inappropriate for acutely ill children and adults due to SIAD-like states 3. Isotonic or near-isotonic fluids should be used 3.

Hypophosphatemia (<0.81 mmol/L)

Classification:

• Mild: <0.81 mmol/L 6
• Moderate: <0.61 mmol/L 6
• Severe: <0.32 mmol/L 6

Prevalence: 60-80% in ICU patients 6, 5.

Urgent review required: Severe hypophosphatemia demands immediate attention due to associations with respiratory failure, prolonged mechanical ventilation weaning, cardiac arrhythmias, and prolonged hospitalization 6.

High-risk scenarios:

• Initiation of kidney replacement therapy 6, 5
• Refeeding syndrome (when nutrition restarted after starvation) 6
• Continuous kidney replacement therapy with losses up to several grams daily 5

Hypomagnesemia (<0.70 mmol/L)

Prevalence: 12% in hospitalized patients; 60-65% in critically ill patients 5.

Urgent review: Severe hypomagnesemia requires correction due to cardiac arrhythmia risk and neuromuscular complications 5.

Special consideration: Regional citrate anticoagulation during kidney replacement therapy causes magnesium-citrate complex formation with substantial effluent losses 5.

Hypocalcemia

Common in kidney disease: Hypocalcemia frequently accompanies hyperphosphatemia in acute kidney injury and chronic kidney disease 6.

Monitoring requirements: Assess calcium, phosphorus, 25(OH) vitamin D, and PTH annually or more frequently in CKD patients 10.

Monitoring Frequency and High-Risk Populations

Close electrolyte monitoring is mandatory in:

• Patients with acute kidney injury, chronic kidney disease, or kidney failure receiving kidney replacement therapy 6, 5
• Critically ill patients (cumulative incidence of electrolyte disorders up to 65%) 6
• Patients with renal dysfunction or shock (check electrolytes regularly in first 24 hours) 12
• Patients receiving RAASi therapy, especially with CKD, diabetes, heart failure, or hyperkalemia history 9

Specific monitoring recommendations:

• Infants and young children with tubulopathies: Every 3-6 months 13
• Stable older children: Every 6-12 months 13
• Adults with chronic conditions: Every 6-12 months 13
• Intensive/prolonged kidney replacement therapy: Frequent monitoring for hypophosphatemia, hypokalemia, and hypomagnesemia 6, 5

Refeeding Syndrome Prevention

Refeeding syndrome occurs when nutrition is reintroduced after acute or chronic starvation, causing precipitous electrolyte falls and fluid shifts 11. The body adapts to undernutrition by down-regulating membrane pumping, causing intracellular potassium, magnesium, calcium, and phosphate leakage with whole-body depletion 11.

Prevention strategy:

• Start feeding at approximately 10 kcal/kg/day in very high-risk patients (not the often-suggested 20 kcal/kg/day) 11
• Provide generous potassium, magnesium, calcium, and phosphate supplementation from the start 11
• Administer thiamine and B vitamins intravenously before feeding begins, continuing at least 3 days 11
• Monitor electrolytes closely during initial feeding period 11

Critical pitfall: Correcting plasma electrolytes before feeding provides false security; severely malnourished patients have massive intracellular deficits (hundreds of mmol) requiring simultaneous feeding to encourage transmembrane transfer 11.

Correlating Biochemistry with Physical Examination

Hyperkalemia Physical Findings:

• Neuromuscular: Muscle weakness, fatigue 13
• Cardiac: Palpitations, potential arrhythmias (though often asymptomatic until severe) 2
• ECG changes: Shortened action potentials, peaked T waves, widened QRS 2

Hyponatremia Physical Findings:

• Mild: Nausea, confusion, lethargy 3
• Severe: Hyponatremic encephalopathy with altered mental status, seizures, coma 3
• Volume assessment: Skin turgor, mucous membranes, jugular venous pressure, edema 11, 1

Hypophosphatemia Physical Findings:

• Respiratory: Worsening respiratory failure, difficulty weaning from mechanical ventilation 6
• Cardiac: Arrhythmias 6
• Neuromuscular: Weakness 6

Dehydration and Salt Wasting (Bartter Syndrome example):

• Clinical signs: Polyuria, rapid weight loss, dehydration, failure to thrive, salt craving, muscle weakness, low blood pressure 13
• Laboratory: Hypochloremic hypokalemic metabolic alkalosis, elevated renin and aldosterone 13

Acute Heart Failure:

• Monitoring: Frequent heart rate, blood pressure, oxygen saturation, fluid balance including urine output 12
• Electrolyte checks: Regular monitoring in first 24 hours if shock or significant renal dysfunction present 12

Key principle: Abnormal serum electrolyte values cannot be interpreted in isolation; they require integration with patient history, volume status, other laboratory values, and clinical presentation 14. Pseudo-hyperkalemia from hemolysis or improper sampling must be excluded by repeat measurement 2.